MTOR and fatty liver disease: Compounds like magnolol (MG), in HepG2 and Wistar rat models, demonstrate therapeutic potential by inhibiting mTOR and activating the Nrf2-ARE pathway, enhancing autophagic flux and reversing hepatic steatosis (156).